Enovis

Enovis EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Enovis (ENOV) as of Nov 5, 2026 is 11.64. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 22.26 — a change of -47.69% (lower).

EV/OCF

11.64

YoY

-47.69%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Enovis is 2025 11.64 . EV/OCF (Enterprise Value to Operating Cash Flow) of Enovis was 2024 22.26 . It decreases by -47.69% lower compared to the previous year.

The Enovis EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
9.71 USD
Jan 1, 2019
26.33 USD
Jan 1, 2020
11.18 USD
Jan 1, 2021
7.44 USD
Jan 1, 2022
-26.49 USD
Jan 1, 2023
12.41 USD
Jan 1, 2024
22.26 USD
Jan 1, 2025
11.64 USD
The Enovis EV/OCF history
YEAREV/OCFYoY
11.64-47.69%
22.26+79.38%
12.41-146.83%
-26.49-455.88%
7.44-33.40%
11.18-57.54%
26.33+171.19%
9.71+12.10%
8.66-7.63%
9.38+170.41%
3.47+40.87%
2.46—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enovis Stock analysis

What does Enovis do? Enovis Corp. generates revenue through its two business segments, Prevention & Recovery and Reconstructive. The Prevention & Recovery segment sells rigid bracing products, orthopedic soft goods, vascular systems, compression garments, and hot and cold therapy products to clinical rehabilitation and sports medicine markets, including recovery sciences products like bone growth stimulators and electrical stimulators for pain management. The Reconstructive segment focuses on knee, hip, shoulder, elbow, foot, ankle, and finger implant products, surgical productivity solutions, and Novastep, a minimally invasive surgery (MIS) foot and ankle solution, targeting healthcare providers and surgical centers. Medical device manufacturers and healthcare institutions are the primary buyers of these products, with the company's solutions addressing both preventive care and reconstructive procedures. The company's product portfolio includes clinically differentiated medical devices designed for specific applications in reconstructive surgery, rehabilitation, pain management, and physical therapy. By manufacturing and distributing these products under its own brand, Enovis Corp. serves healthcare providers seeking innovative solutions for patient recovery and surgical efficiency. The Prevention & Recovery segment's offerings, such as compression garments and therapy products, cater to both clinical and sports medicine applications, while the Reconstructive segment's implants and surgical tools are used in orthopedic procedures worldwide. The company's focus on minimally invasive solutions like Novastep enhances its appeal to surgeons and hospitals looking to reduce patient recovery times. Enovis Corp. targets healthcare providers, surgical centers, and rehabilitation facilities as key customers for its medical devices. The Prevention & Recovery segment's products, including bone growth stimulators and electrical stimulators, are sold to clinical rehabilitation and sports medicine markets, while the Reconstructive segment's knee, hip, and foot implant products are distributed to orthopedic surgical centers. The company's revenue streams are derived from direct sales of these branded medical devices, with no mention of third-party partnerships or external distribution channels in the business description. Enovis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enovis stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Enovis is 11.64 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Enovis changed from 22.26 to 11.64, representing a -47.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Enovis since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Enovis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Enovis

All Key Metrics — Enovis